The global Just – Evotec Biologics network includes two US-based and one EU-based site, offering biotherapeutics discovery, cell line, analytical, process development capabilities as well as early clinical to commercial cGMP biomanufacturing.

Furthermore, we can leverage the whole Evotec network globally to support integrated or complementary antibody/biologics activities and benefit from therapeutic area experts’ input.

Establishing our facilities in geopolitical stable regions is another contributor to our value proposition. 

We want to be close to our partners, offering stable and efficient supply chains. Additionally, we comply with local regulations to meet your quality standards and access US and EU networks and expertise.

We offer access to commercial capacity within our J.POD facilities network but can also enable strategic Biopharma partners with dedicated J.POD facilities leveraging our proprietary continuous manufacturing technology platform.

As part of our mission to expand global access to patients, we are also ready to enable fast J.POD deployment to face pandemics and explore such strategies with governments and non-profit organizations.